Hospital pharmacy teams have spent years getting good at spending less. Finding the cheaper equivalent, negotiating a better contract, catching and fixing overcharges. It’s worked, and it’s still the top financial priority for most teams: 72% of pharmacy teams leaders are tasked with reducing drug spend this year.
But a focus solely on cost has a blind spot. In outpatient settings, specialty drugs and biosimilars are more than line items – they’re often revenue drivers for the health system. Two therapeutically equivalent products can carry a net margin difference of $2,000 per vial. Compare them on acquisition cost alone, and pharmacy teams would never see that gap, let alone capture it.
The Cost Center Myth
Pharmacy has historically been framed as a cost center, but that framing is incomplete. Every purchasing decision for a reimbursable drug is also a revenue decision: pharmacy generates income through drug administration, infusion services, and outpatient dispensing. The trouble is that acquisition cost and reimbursement have always lived in separate systems.
While procurement tools show what you paid, reimbursement sits in billing systems, finance spreadsheets, and ASP lookup tables that require manual cross-referencing. So pharmacy teams optimized what they could see, with the revenue side largely invisible.
Reimbursement Data Changes the Equation
Layer reimbursement data into procurement decisions and the math can shift entirely.
Consider a specialty drug switch that saves $400 per vial on acquisition cost, but reimburses $1,800 less under Medicare Part B. On a cost-only basis, that looks like a win. With margin visibility, it’s clearly a loss.
The inverse is equally important. A biosimilar that costs slightly more to acquire may reimburse at a significantly higher rate, turning what looked like a neutral or unfavorable switch into a meaningful revenue opportunity.
Margin Optimization In Practice
Pharmacy teams often use spend optimization tools to identify cost-saving opportunities through NDC and supplier changes, contract management, and overcharge identification. A newer category of tools, such as Bluesight’s Medicare Margin Optimizer, add reimbursement data into buying recommendations, showing both cost impact and estimated margin impact side by side.
This matters most for drugs administered in outpatient settings, where care is shifting fast: outpatient visits rose 9.8% year-over-year in 2025, and outpatient services now account for 57% of hospital revenue. High-cost medications, especially biologics and biosimilars, play an outsized role in that outpatient margin – and, as previously noted, two therapeutically comparable products can carry a $2,000+ per-vial swing. Viewing reimbursement data at the point of decision can mean the difference between a net loss and a positive margin.
With this depth of insight, purchasing teams can view:
- Cost savings: switches to a cheaper therapeutic equivalent that lowers acquisition cost
- Revenue opportunities: switches where the alternative drug reimburses at a higher rate, increasing revenue even if acquisition cost is similar
- Double wins: switches where a single change lowers acquisition cost and raises reimbursement at the same time
Today’s tools rely on publicly available Medicare Part B reimbursement data to provide directional insight into revenue opportunities. The next step is to ingest a health system’s own claims data across payers, moving the calculation from a directional signal to a precise margin calculation for each purchasing decision.
The Bottom Line
Cost savings will always be critical to the pharmacy’s bottom line. Now, margin visibility gives pharmacy leaders a new number to bring into the finance conversation – not just what the department saved, but what it helped the health system earn.
As hospitals continue shifting care to outpatient settings, the organizations that succeed will be those that treat pharmacy not only as a steward of costs, but as a strategic contributor to health system revenue. To see how Bluesight can inform your procurement decision-making with cost and margin data, check out CostCheck today.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
